ReviewMolecular biology reports2026
Targeting NAV2-mediated Wnt/β-catenin signaling in rheumatoid arthritis: current evidence and emerging therapeutic approaches.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent activation of pathogenic signaling pathways driven by circulating mediators and intracellular factors that enhance the chronic synovial inflammation and progressive joint damage in rheumatoid arthritis (RA). Advances in the development of disease-modifying antirheumatic drugs (DMARDs) and biologics are significantly improved disease control. Still, the persistence of multidrug resistance and progressive structural damage in many reported cases indicates that multiple molecular targets in RA progression are unclear. This gap highlights the urgent need to identify new molecular pathways for next-generation therapies, which may help prevent synovial inflammation, cartilage degradation, and bone erosion arising from complex interactions among immune cells, cytokines, and dysregulated signaling pathways. The pathophysiology of RA is caused by genetic risk, environmental triggers, and dysregulated immune responses that activate fibroblast-like synoviocytes (FLS) and stimulate osteoclastogenesis. Several intracellular pathways, including JAK-STAT, PI3K-AKT, MAPK, SYK-BTK, Notch, NF-κB, and Wnt/β-catenin, play a significant role in disease progression. Among the emerging molecular pathways, NAV2-mediated modulation of Wnt/β-catenin signaling acts as a regulator for fibroblast-like synoviocyte (FLS) proliferation, cytoskeletal remodeling, and pannus formation, thereby disrupting the osteoblast-osteoclast balance and accelerating bone destruction. This identifies the NAV2-Wnt/β-catenin pathway as a promising therapeutic target for controlling structural deterioration and joint damage. In this review, we emphasize the need for a deeper understanding of interconnected molecular signaling pathways underlying RA pathogenesis, with particular focus on the NAV2-Wnt/β-catenin pathway due to its potential in reducing synovial inflammation, limiting structural damage, and improving responses to DMARDs and biologics; additionally, herbal-drug combinations may offer additive therapeutic benefits, but they require rigorous clinical validation to ensure safety and minimize adverse interactions.
Indexed as
Identifiers
42047909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.